On March 26, 2014, BF Investment Enterprises, Ltd. sold 421,268 shares TherapeuticsMD, Inc. (NYSEMKT:TXMD) common stock, par value $0.001 (“Common Stock”), in an underwritten secondary public offering (the “Offering”), pursuant to an Underwriting Agreement, between the Company. TherapeuticsMD Inc. (NYSEMKT:TXMD) shares after opening at $5.95 moved to $5.95 on last trade day and at the end of the day closed at $5.63. Company price to sales ratio in past twelve months was calculated as 92.81 and price to cash ratio as 15.07. TherapeuticsMD Inc. (NYSEMKT:TXMD) showed a negative weekly performance of -6.94%.
On April 3, 2014, Retrophin, Inc. (NASDAQ:RTRX) provided notice to the wholesaler of its Chenodal product that effective immediately. Retrophin Inc. (NASDAQ:RTRX) shares fell -9.63% in last trading session and ended the day on $21.11. RTRX return on assets is -707.30%. Retrophin Inc. (NASDAQ:RTRX) yearly performance is 302.10%.
KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO) share price has entered into oversold territory with an RSI value of 29.9. KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO) shares moved down -4.17% in last trading session and was closed at $2.53, while trading in range of $2.29 – $2.71. KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO) year to date (YTD) performance is -42.76%.
Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, on 31 march announced full financial results for fiscal year ended December 31, 2013. Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) weekly performance is 3.04%. On last trading day company shares ended up $6.11. Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) distance from 50-day simple moving average (SMA50) is 12.85%.